obesity drug news today glp-1 october 21 2025 Market CVS obesity drug deal puts
Description
The protective cardiovascular effects of GLP-1RAs can be through improving glycemic control, as reducing HbA1c can improve blood pressure, body weight, hyperlipoproteinemia, and inflammation
Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
Instead, it teamed up with insulin to make the body's existing insulin work better, lowering blood glucose more effectively
GIP/GLP-1 co-agonists, developed by merging the respective peptide sequences, potently lower body weight in rodents and humans 27,28
Am J Physiol Endocrinol Metab (1982) 242:E20613
